negative symptoms | CARLAT PUBLISHING

Research Update

Negative Symptoms of Schizophrenia: A New Target for TMS?

October 1, 2024

Briana Tillman, MD. Dr. Tillman has no financial relationships with companies related to this material.

The negative symptoms of schizophrenia are notoriously difficult to address with traditional treatments. The meta-analysis suggests TMS can significantly improve negative symptoms and may offer a promising new treatment approach.

Negative Symptoms of Schizophrenia

January 1, 2024

Chris Aiken, MD and Paul Riordan, MD.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Paul Riordan, MD. Assistant Consulting Professor of Psychiatry, Duke University, Durham, NC.

The authors have no financial relationships with companies related to this material.

Negative symptoms are the primary cause of disability in schizophrenia, and we identify a few antipsychotics and a few add-on therapies that can help.

Pimavanserin Improves Negative Symptoms of Schizophrenia

January 1, 2023

Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

Pimavanserin (Nuplazid) is a novel antipsychotic with a narrow FDA-approval in psychosis due to Parkinson’s disease. This large randomized trial tested the drug in negative symptoms of
schizophrenia.